ProQR Therapeutics (NASDAQ: PRQR) has announced that it is ceasing further R & D on its antisense inherited retinal eye disease program.
ProQR has been struggling since announcing in February that the Phase 2/3 pivotal trial in its lead program of sepofarsen in LCA failed to meet both primary and secondary endpoints. After teasing out some positive data from additional analysis of the data, the company consulted with both the EMA and FDA, but it became clear that a further pivotal trial would be required. Instead, ProQR has opted to seek a strategic partner for its ophthalmology portfolio.
The company will now focus on its Axiomer RNA-editing technology platform in the therapeutic areas of liver and CNS, which are already focus areas of its research partnership with Eli Lilly.
PRQR closed yesterday with a market cap of US$60m. Cash reserves at 30/06 were US$160m.
https://www.proqr.com/press-release...technology-and-partner-ophthalmology-programs
https://medcitynews.com/2022/08/aft...e-eye-proqr-therapeutics-pivots-to-liver-cns/
https://hotcopper.com.au/threads/sepofarsen-fails-in-pivotal-trial.6580268/?post_id=59530985
https://hotcopper.com.au/threads/the-attraction-of-reversible-editing.6283772/?post_id=56037509
https://hotcopper.com.au/threads/progress-updates.6076458/page-10?post_id=53480861
- Forums
- ASX - By Stock
- PYC
- Ann: PYC Therapeutics Investor Call - 18 August 2022
Ann: PYC Therapeutics Investor Call - 18 August 2022, page-10
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.0¢ |
Change
-0.010(8.33%) |
Mkt cap ! $513.2M |
Open | High | Low | Value | Volume |
12.0¢ | 12.5¢ | 11.0¢ | $383.6K | 3.159M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 169997 | 11.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.5¢ | 1549 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 79088 | 0.110 |
5 | 392419 | 0.105 |
10 | 839229 | 0.100 |
2 | 13721 | 0.099 |
4 | 170204 | 0.098 |
Price($) | Vol. | No. |
---|---|---|
0.120 | 1000000 | 2 |
0.125 | 49465 | 1 |
0.130 | 993436 | 16 |
0.135 | 488212 | 5 |
0.140 | 453116 | 2 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
PYC (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online